Results 81 to 90 of about 210,319 (126)
Some of the next articles are maybe not open access.
Neuroprotection and dopamine agonists
Neurology, 2002Several factors are known to be capable of inducing relatively selective dopaminergic cell death in the substantia nigra and inducing the clinical features that characterize Parkinson's disease (PD). Neuronal toxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) can induce parkinsonism in human and animal models, and rotenone, another ...
openaire +2 more sources
Dopamine Agonists in the Treatment of Schizophrenia
1986Publisher Summary Behavioral, neurochemical, ligand binding, and single cell unit recording studies suggest the existence of two distinct classes of dopamine (DA) receptors: autoreceptors, which are present on the membranes of dopamine neurons, and postsynaptic receptors located on the neurons with which dopamine neurons synapse.
DEL ZOMPO, MARIA +3 more
openaire +4 more sources
Neurology, 2002
Although all dopaminergic drugs are effective in reducing tremor, no single drug has been shown to be clearly superior in the treatment of tremor. Levodopa produces a mean improvement of 30 to 50% in the Unified Parkinson's Disease Rating Scale (UPDRS) subtest for rest tremor. Comparable improvement is achieved with the dopamine agonists.
openaire +2 more sources
Although all dopaminergic drugs are effective in reducing tremor, no single drug has been shown to be clearly superior in the treatment of tremor. Levodopa produces a mean improvement of 30 to 50% in the Unified Parkinson's Disease Rating Scale (UPDRS) subtest for rest tremor. Comparable improvement is achieved with the dopamine agonists.
openaire +2 more sources
Expert Opinion on Pharmacotherapy, 2002
(2002). Synthetic dopamine agonists. Expert Opinion on Pharmacotherapy: Vol. 3, No. 4, pp. 363-364.
openaire +2 more sources
(2002). Synthetic dopamine agonists. Expert Opinion on Pharmacotherapy: Vol. 3, No. 4, pp. 363-364.
openaire +2 more sources
Dopamine agonists in Parkinson’s disease
Expert Opinion on Investigational Drugs, 2003Levodopa (LD), the immediate precursor of dopamine, is the most effective agent in the treatment of Parkinson's disease (PD). While quite successful in treating the primary motor deficits of PD, most patients eventually develop LD-related motor fluctuation, dyskinesias and other adverse effects associated with chronic LD therapy.
Ron, Tintner, Joseph, Jankovic
openaire +2 more sources
Dopamine and dopamine receptor agonists in cardiovascular therapy
Critical Care Medicine, 1990Dopamine (DA)--previously regarded simply as the precursor of norepinephrine--is now known to have its own unique effects on cardiovascular regulation which are mediated, in part, by activating specific DA receptors. DA has long been used in the treatment of shock and heart failure.
M B, Murphy, W J, Elliott
openaire +2 more sources
Dopamine agonists in Parkinson's disease
Neurology, 1995The main pathologic hallmark of Parkinson's disease is a degeneration of the dopaminergic cells in the substantia nigra, pars compacta and--to a lesser extent--in the ventral tegmental area. Striatal dopamine concentrations are significantly reduced before clinical symptoms become apparent.
E C, Wolters +3 more
openaire +2 more sources
Treatment of Acromegaly with Dopamine Agonists
Endocrinology and Metabolism Clinics of North America, 1992This article reviews the current understanding of how dopamine agonists stimulate growth hormone secretion in normal individuals, yet suppress growth hormone secretion in acromegaly patients. Although bromocriptine normalizes growth hormone or somatomedin C hypersecretion in a minority of patients, a significant number of subjects have a clinical ...
C A, Jaffe, A L, Barkan
openaire +2 more sources
Dopamine agonists in schizophrenia: a review
European Neuropsychopharmacology, 1995Although it is unlikely that the different types of course and severity of schizophrenia are caused by one neurochemical abnormality alone, indirect pharmacological evidence still suggests a relative excess of dopaminergic activity being implicated in the pathogenesis of most of the schizophrenic symptoms, e.g. positive symptomatology.
O, Benkert +2 more
openaire +2 more sources
Alopecia induced by dopamine agonists
Neurology, 2002We report two women with PD who developed alopecia while being treated with the dopamine agonists pramipexole and ropinirole. The alopecia reversed partially after the drugs were discontinued. Both women were postmenopausal and had no history of hair loss or other dermatologic disorders.
Rowena E, Tabamo, Alessandro, Di Rocco
openaire +2 more sources